MPN Hub
The MPN Hub is an open-access online resource, dedicated to providing healthcare professionals with balanced, credible, and up-to-date medical education in MPN. Our aim is to enhance knowledge in MPN, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
The MPN Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
The MPN Hub is an independent medical education platform, sponsored by pharmaceutical companies; a full list of our supporters can be found on our website mpn-hub.com. The funders are allowed no direct influence on our content.
ASH 2025 | Nuvisertib + momelotinib in patients with R/R MF: Phase I/II findings
How might extended-release formulations of ruxolitinib benefit patients with MF?
What is on the horizon for the treatment of myelofibrosis-related anemia?
What are the unmet needs in the management of myelofibrosis-related anemia?
How I treat myelofibrosis-related anemia
Novel targeted therapies for R/R MF: PIM1 kinase inhibition
Novel treatments: Momelotinib and luspatercept
Anemia as an unmet need: Impacts on QoL and survival outcomes
Symposium | Anemia in myelofibrosis: Q&A
Symposium | Sequencing therapies: Optimizing treatment for myelofibrosis
Symposium | The treatment landscape for patients with myelofibrosis and anemia
Symposium | Anemia in myelofibrosis: Impact on patient outcomes
Clinical trial round-up: Treating anemia in patients with myelofibrosis
Momelotinib: Impact on transfusion dependence and QoL in MF
How might luspatercept benefit patients with myelofibrosis?
Meaningful biomarkers in myeloproliferative neoplasms
What more can be done to improve treatment for patients with polycythemia vera?
Meaningful biomarkers in myeloproliferative neoplasms: Q&A session
Reconsidering the place of BMT, and BMT reporting consistency: Q&A session
Reconsidering the place of bone marrow transplant (BMT), and BMT reporting consistency
What novel therapies are under investigation for the treatment of high-risk MPN?
Current clinical landscape in anemic myelofibrosis
Optimal treatment sequencing in anemic myelofibrosis
Treatment sequencing and ongoing clinical trials in anemic myelofibrosis
Q&A session
How do TP53 mutations impact survival in patients with MPN?
Promising new drugs in MPN therapy
Can ruxolitinib replace hydroxyurea as a frontline therapy for PV?
Thrombotic / hemorrhagic complications
The role of AI in the future of MPN bone marrow histopathology